NCT06684522View on ClinicalTrials.gov

Upadacitinib As a Novel Treatment for Refractory Eyelid Dermatitis

EARLY_PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions

Eyelid Dermatitis

Interventions

DRUG

Upadacitinib 15 MG

Upadacitinib 15mg daily

Trial Locations (1)

60611

Northwestern University Department of Dermatology, Chicago

All Listed Sponsors

lead

Northwestern University

OTHER